---
title: "Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274639663.md"
description: "Wuhan YZY Biopharma Co., Ltd. has received FDA approval for its Investigational New Drug application for M701, a bispecific antibody targeting EpCAM and CD3. This approval allows for a phase Ib/II clinical trial in the U.S. for patients with malignant pleural effusion from advanced epithelial tumors. The company aims to address significant unmet medical needs in oncology. The latest analyst rating for the stock (HK:2496) is a Hold with a price target of HK$8.00, and the current market cap is HK$1.53B."
datetime: "2026-02-03T10:40:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274639663.md)
  - [en](https://longbridge.com/en/news/274639663.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274639663.md)
---

# Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest announcement is out from Wuhan YZY Biopharma Co., Ltd. Class H ( (HK:2496) ).

Wuhan YZY Biopharma Co., Ltd. has secured U.S. FDA approval of an Investigational New Drug application for M701, a recombinant bispecific antibody targeting EpCAM and CD3, positioning the company within the innovative oncology biopharmaceutical space focused on advanced tumor complications. The approval clears the way for an open-label, multicenter phase Ib/II clinical trial in the United States to evaluate intrapleural M701 in patients with malignant pleural effusion caused by advanced epithelial tumors, potentially expanding the firm’s international clinical footprint and addressing a significant unmet need where current treatment options are largely palliative, while underscoring both the opportunity and the development risks for stakeholders.

The most recent analyst rating on (HK:2496) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Wuhan YZY Biopharma Co., Ltd. Class H stock, see the HK:2496 Stock Forecast page.

**More about Wuhan YZY Biopharma Co., Ltd. Class H**

Wuhan YZY Biopharma Co., Ltd. is a biopharmaceutical company engaged in the research and development of innovative antibody-based therapies, including bispecific antibodies, targeting serious oncology indications and other diseases with high unmet medical need in global markets.

**Average Trading Volume:** 6,160

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$1.53B

### Related Stocks

- [02496.HK](https://longbridge.com/en/quote/02496.HK.md)

## Related News & Research

- [ZAWYA: SEHA’s Tawam Hospital to host the UAE and region’s first certified workshop on low-dose radiotherapy for benign diseases](https://longbridge.com/en/news/290536060.md)
- [Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancers](https://longbridge.com/en/news/290619996.md)
- [Exchange Seeks Clarification from Balaxi Pharmaceuticals on March 2026 Results](https://longbridge.com/en/news/290641193.md)
- [SSY Group Wins NMPA Approvals for Parkinson’s and Respiratory Drugs](https://longbridge.com/en/news/290402091.md)
- [GEA Group Aktiengesellschaft Targets EUR 7B Revenue, Higher Margins by 2030](https://longbridge.com/en/news/290448472.md)